Krystal Biotech (KRYS) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Goldman Sachs | Maintained | Buy | $441.00 | Sep 24, 2026 |
| B of A Securities | Maintained | Buy | $400.00 from $392.00 | Sep 21, 2026 |
| RBC Capital | Initiated Coverage | Outperform | $400.00 | Aug 14, 2026 |
| Citigroup | Maintained | Buy | $386.00 from $378.00 | Aug 4, 2026 |
| B of A Securities | Maintained | Buy | $396.00 from $364.00 | Jul 14, 2026 |
| TD Cowen | Maintained | Buy | $403.00 from $306.00 | Jun 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $361.00 from $310.00 | Jun 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $310.00 | Jun 1, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $310.00 | May 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $310.00 | May 18, 2026 |
| Evercore ISI Group | Maintained | Outperform | $300.00 from $295.00 | May 5, 2026 |
| Citigroup | Maintained | Buy | $378.00 from $371.00 | May 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $310.00 | May 4, 2026 |
| Wolfe Research | Initiated Coverage | Peer Perform | — | Mar 27, 2026 |
| Guggenheim | Maintained | Buy | $284.00 from $224.00 | Feb 25, 2026 |
| Chardan Capital | Maintained | Buy | $323.00 from $220.00 | Feb 18, 2026 |
| Citigroup | Maintained | Buy | $371.00 from $336.00 | Feb 18, 2026 |
| Jefferies | Maintained | Buy | $371.00 from $310.00 | Feb 17, 2026 |
| Goldman Sachs | Maintained | Buy | $327.00 from $206.00 | Feb 2, 2026 |
| B of A Securities | Maintained | Buy | $318.00 from $288.00 | Jan 22, 2026 |
Frequently asked questions
What is the price target for KRYS stock?
The average 12-month analyst price target for Krystal Biotech (KRYS) is $406.75, with a high estimate of $441.00 and a low of $386.00, across 4 analysts.
Is KRYS a buy, sell, or hold?
Analysts covering Krystal Biotech currently average a Buy rating: 12 buy, 1 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for KRYS?
The average price target of $406.75 implies 26.65% upside from the last price of $321.16.
What is the latest analyst rating on KRYS?
On Sep 24, 2026, Goldman Sachs maintained Krystal Biotech at Buy with a price target of $441.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.